ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income( 1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA( 2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previously Provided 2026-2029 Financial Guidance RAMSEY, N.J. and BOCA RATON, Fla.

Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.

RAMSEY, N.J. and BOCA RATON, Fla.

Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.

Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.

Campbell and CO Investment Adviser LLC acquired a new stake in ADMA Biologics Inc (NASDAQ: ADMA) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 64,535 shares of the biotechnology company's stock, valued at approximately $946,000. Other hedge funds also recently modified their

ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.

In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.

ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow Estimate of ~$40 Million in 4Q 2025 2026 Expected to be ADMA's First Full Year of Yield-Enhanced Production, Supporting Anticipated Sustained Margin Expansion Strategic Plasma Network Repositioning Expected to Enhance Margins and Strengthen Long-Term Supply Visibility Positive, Statistically Significant Real-World ASCENIV™ Outcomes to be Presented at CIS in May 2026; Additional ASCENIV Data Expected Throughout 2026 Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Submission in 2026 Ongoing Share Repurchases and Capital Structure Strengthening to Enhance Stockholder Value FY 2026 and FY 2027 Revenue Expected to be Approximately $635 Million and $775 Million, Respectively FY 2026 and FY 2027 Adjusted Net Income Expected to be Approximately $255 Million and $315 Million, Respectively FY 2026 and FY 2027 Adjusted EBITDA Expected to be Approximately $360 Million and $455 Million, Respectively ADMA Targets Greater Than $1.1 Billion in Annual Revenue in FY 2029, Representing ~20% CAGR(3) ADMA Targets Greater Than $700 Million in Adjusted EBITDA in FY 2029, Representing ~30% CAGR RAMSEY, N.J. and BOCA RATON, Fla.